Previous 10 | Next 10 |
Co-Diagnostics JV CoSara Receives Clearance from Indian FDA for Chikungunya and Dengue Tests PR Newswire SALT LAKE CITY , Sept. 16, 2021 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company"), a molecular diagnostics company with a unique, p...
Co-Diagnostics, Inc. CEO to Participate in Panel Discussion with Scott Gottlieb, M.D., at H.C. Wainwright 2021 Annual Global Investor Conference Company CEO and CFO will also be conducting a presentation that will be available on-demand PR Newswire SALT LAKE CITY ...
Co-Diagnostics, Inc. SARS-CoV-2 Test Used in New Community Surveillance Method in Italy Peer-reviewed results describe the Company's test being used to confirm the presence of the virus on community waste, including mutated strains PR Newswire SALT LAKE CITY , ...
Co-Diagnostics, Inc. To Present At 13th Next Generation Dx Summit In Washington, D.C. PR Newswire SALT LAKE CITY , Aug. 23, 2021 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company"), a molecular diagnostics company with a unique, patente...
FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – August 19, 2021 – With the number of new COVID cases surging, fueled by a highly contagious Delta variant and only 50% of the US population having been vaccinated, the need for rapid tes...
Co-Diagnostics shares rallied after the company posted strong quarterly results. Total addressable market expanding. Stock steeply undervalued and scores a Seeking Alpha Quant Score of 'A' on key metrics. For further details see: Why Co-Diagnostics Is A Solid Covid-19 Pl...
Co-Diagnostics (NASDAQ: CODX) was an investor-pleasing machine at the tail end of the week. After reporting highly encouraging Q2 earnings after market close on Thursday, the company's stock unsurprisingly leapt by just under 10% the following day. Co-Diagnostics beat every coll...
Co-Diagnostics, Inc. (CODX) Q2 2021 Earnings Conference Call August 12, 2021 04:30 PM ET Company Participants Andrew Benson - Head of Investor Relations Dwight Egan - Chief Executive Officer Brian Brown - Chief Financial Officer Conference Call Participants Yi Chen - H.C. Wainwright Theodore ...
Co-Diagnostics (NASDAQ:CODX): Q2 GAAP EPS of $0.33 beats by $0.11. Revenue of $27.4M (+14.0% Y/Y) beats by $6.63M. Press Release Q3 Outlook: Revenue to be in the range of $23.0 million to $25.0 million Diluted earnings per share forecasted to be in the $0.19 to $0.22 range. For further...
Co-Diagnostics Reports Strong Second Quarter 2021 Financial Results Solid quarterly results highlighted by revenue of $27.4 million, pre-tax income of $11.9 million and diluted EPS of $0.33 PR Newswire SALT LAKE CITY , Aug. 12, 2021 /PRNewswire/ -- Co-Di...
News, Short Squeeze, Breakout and More Instantly...
Co-Diagnostics, Inc. to Host Booth and Discuss Advancing POC/OTC Diagnostics at ADLM 2024 in Chicago PR Newswire SALT LAKE CITY , July 29, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company wi...
Co-Diagnostics, Inc. Announces Second Quarter 2024 Earnings Release Date and Webcast PR Newswire SALT LAKE CITY , July 25, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the developme...
Co-Diagnostics, Inc. Expands Vector Control Customer Base to 25 Customers across 15 U.S. States PR Newswire SALT LAKE CITY , July 2, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx™"), a molecular diagnostics company w...